Literature DB >> 22188997

Molecular preservation by extraction and fixation, mPREF: a method for small molecule biomarker analysis and histology on exactly the same tissue.

Jeffrey R Shuster1, Raymond S Lance, Dean A Troyer.   

Abstract

BACKGROUND: Histopathology is the standard method for cancer diagnosis and grading to assess aggressiveness in clinical biopsies. Molecular biomarkers have also been described that are associated with cancer aggressiveness, however, the portion of tissue analyzed is often processed in a manner that is destructive to the tissue. We present here a new method for performing analysis of small molecule biomarkers and histology in exactly the same biopsy tissue.
METHODS: Prostate needle biopsies were taken from surgical prostatectomy specimens and first fixed, each in a separate vial, in 2.5 ml of 80% methanol:water. The biopsies were fixed for 24 hrs at room temperature and then removed and post-processed using a non-formalin-based fixative (UMFIX), embedded, and analyzed by hematoxylin and eosin (H&E) and by immunohistochemical (IHC) staining. The retained alcohol pre-fixative was analyzed for small molecule biomarkers by mass spectrometry.
RESULTS: H&E analysis was successful following the pre-fixation in 80% methanol. The presence or absence of tumor could be readily determined for all 96 biopsies analyzed. A subset of biopsy sections was analyzed by IHC, and cancerous and non-cancerous regions could be readily visualized by PIN4 staining. To demonstrate the suitability for analysis of small molecule biomarkers, 28 of the alcohol extracts were analyzed using a mass spectrometry-based metabolomics platform. All extracts tested yielded successful metabolite profiles. 260 named biochemical compounds were detected in the alcohol extracts. A comparison of the relative levels of compounds in cancer containing vs. non-cancer containing biopsies showed differences for 83 of the compounds. A comparison of the results with prior published reports showed good agreement between the current method and prior reported biomarker discovery methods that involve tissue destructive methods.
CONCLUSIONS: The Molecular Preservation by Extraction and Fixation (mPREF) method allows for the analysis of small molecule biomarkers from exactly the same tissue that is processed for histopathology.

Entities:  

Year:  2011        PMID: 22188997      PMCID: PMC3280163          DOI: 10.1186/1472-6890-11-14

Source DB:  PubMed          Journal:  BMC Clin Pathol        ISSN: 1472-6890


  54 in total

1.  Interobserver reproducibility of Gleason grading of prostatic carcinoma: general pathologist.

Authors:  W C Allsbrook; K A Mangold; M H Johnson; R B Lane; C G Lane; J I Epstein
Journal:  Hum Pathol       Date:  2001-01       Impact factor: 3.466

2.  Evaluation of non-formalin tissue fixation for molecular profiling studies.

Authors:  John W Gillespie; Carolyn J M Best; Verena E Bichsel; Kristina A Cole; Susan F Greenhut; Stephen M Hewitt; Mamoun Ahram; Yvonne B Gathright; Maria J Merino; Robert L Strausberg; Jonathan I Epstein; Stanley R Hamilton; Gallya Gannot; Galina V Baibakova; Valerie S Calvert; Michael J Flaig; Rodrigo F Chuaqui; Judi C Herring; John Pfeifer; Emmanuel F Petricoin; W Marston Linehan; Paul H Duray; G Steven Bova; Michael R Emmert-Buck
Journal:  Am J Pathol       Date:  2002-02       Impact factor: 4.307

Review 3.  NMR-based metabolomics approach to target biomarkers for human prostate cancer.

Authors:  Kate W Jordan; Leo L Cheng
Journal:  Expert Rev Proteomics       Date:  2007-06       Impact factor: 3.940

4.  Immunohistochemical demonstration of oestrogen and progesterone receptors: correlation of standards achieved on in house tumours with that achieved on external quality assessment material in over 150 laboratories from 26 countries.

Authors:  A Rhodes; B Jasani; A J Balaton; K D Miller
Journal:  J Clin Pathol       Date:  2000-04       Impact factor: 3.411

Review 5.  Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer.

Authors:  Robin K Kelley; Stephanie L Van Bebber; Kathryn A Phillips; Alan P Venook
Journal:  J Natl Compr Canc Netw       Date:  2011-01       Impact factor: 11.908

6.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group.

Authors:  Melissa K Tuck; Daniel W Chan; David Chia; Andrew K Godwin; William E Grizzle; Karl E Krueger; William Rom; Martin Sanda; Lynn Sorbara; Sanford Stass; Wendy Wang; Dean E Brenner
Journal:  J Proteome Res       Date:  2009-01       Impact factor: 4.466

8.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

9.  The genomic complexity of primary human prostate cancer.

Authors:  Michael F Berger; Michael S Lawrence; Francesca Demichelis; Yotam Drier; Kristian Cibulskis; Andrey Y Sivachenko; Andrea Sboner; Raquel Esgueva; Dorothee Pflueger; Carrie Sougnez; Robert Onofrio; Scott L Carter; Kyung Park; Lukas Habegger; Lauren Ambrogio; Timothy Fennell; Melissa Parkin; Gordon Saksena; Douglas Voet; Alex H Ramos; Trevor J Pugh; Jane Wilkinson; Sheila Fisher; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jonathan W Simons; Naoki Kitabayashi; Theresa Y MacDonald; Philip W Kantoff; Lynda Chin; Stacey B Gabriel; Mark B Gerstein; Todd R Golub; Matthew Meyerson; Ashutosh Tewari; Eric S Lander; Gad Getz; Mark A Rubin; Levi A Garraway
Journal:  Nature       Date:  2011-02-10       Impact factor: 49.962

10.  Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study.

Authors:  P Eschwège; S Moutereau; S Droupy; R Douard; J-L Gala; G Benoit; M Conti; P Manivet; S Loric
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more
  9 in total

1.  Cancer-Specific Production of N-Acetylaspartate via NAT8L Overexpression in Non-Small Cell Lung Cancer and Its Potential as a Circulating Biomarker.

Authors:  Tzu-Fang Lou; Deepa Sethuraman; Patrick Dospoy; Pallevi Srivastva; Hyun Seok Kim; Joongsoo Kim; Xiaotu Ma; Pei-Hsuan Chen; Kenneth E Huffman; Robin E Frink; Jill E Larsen; Cheryl Lewis; Sang-Won Um; Duk-Hwan Kim; Jung-Mo Ahn; Ralph J DeBerardinis; Michael A White; John D Minna; Hyuntae Yoo
Journal:  Cancer Prev Res (Phila)       Date:  2015-10-28

Review 2.  Metabolomic imaging of prostate cancer with magnetic resonance spectroscopy and mass spectrometry.

Authors:  Eva-Margarete Spur; Emily A Decelle; Leo L Cheng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-03       Impact factor: 9.236

Review 3.  Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.

Authors:  Rachel S Kelly; Matthew G Vander Heiden; Edward Giovannucci; Lorelei A Mucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-06       Impact factor: 4.254

4.  Comparison of 18F-FACBC and 11C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse: preliminary results.

Authors:  Cristina Nanni; Riccardo Schiavina; Stefano Boschi; Valentina Ambrosini; Cinzia Pettinato; Eugenio Brunocilla; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-17       Impact factor: 9.236

5.  Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies.

Authors:  Meredith V Brown; Jonathan E McDunn; Philip R Gunst; Elizabeth M Smith; Michael V Milburn; Dean A Troyer; Kay A Lawton
Journal:  Genome Med       Date:  2012-04-30       Impact factor: 11.117

6.  Metabolic heterogeneity signature of primary treatment-naïve prostate cancer.

Authors:  Dong Lin; Susan L Ettinger; Sifeng Qu; Hui Xue; Noushin Nabavi; Stephen Yiu Chuen Choi; Robert H Bell; Fan Mo; Anne M Haegert; Peter W Gout; Neil Fleshner; Martin E Gleave; Michael Pollak; Colin C Collins; Yuzhuo Wang
Journal:  Oncotarget       Date:  2017-04-18

Review 7.  Prostate cancer diagnosis and characterization with mass spectrometry imaging.

Authors:  Annika Kurreck; Lindsey A Vandergrift; Taylor L Fuss; Piet Habbel; Nathalie Y R Agar; Leo L Cheng
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-12-05       Impact factor: 5.554

8.  Metabolite Analysis and Histology on the Exact Same Tissue: Comprehensive Metabolomic Profiling and Metabolic Classification of Prostate Cancer.

Authors:  Tao Huan; Dean A Troyer; Liang Li
Journal:  Sci Rep       Date:  2016-08-31       Impact factor: 4.379

9.  Simultaneous Detection of Zinc and Its Pathway Metabolites Using MALDI MS Imaging of Prostate Tissue.

Authors:  Maria K Andersen; Sebastian Krossa; Therese S Høiem; Rebecca Buchholz; Britt S R Claes; Benjamin Balluff; Shane R Ellis; Elin Richardsen; Helena Bertilsson; Ron M A Heeren; Tone F Bathen; Uwe Karst; Guro F Giskeødegård; May-Britt Tessem
Journal:  Anal Chem       Date:  2020-01-28       Impact factor: 6.986

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.